SCHEMBL3969724

SCHEMBL3969724

[CH2]Oc1ccnc2nc[nH]c12

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.45
ALDH1A1 P00352 1/20 0.42
PDPK1 O15530 1/20 0.38
PI4KA P42356 2/20 0.37
PI4K2B Q8TCG2 2/20 0.37
PI4K2A Q9BTU6 2/20 0.37
PI4KB Q9UBF8 2/20 0.37
LMNA P02545 1/20 0.37
DRD3 P35462 1/20 0.37
XDH P47989 1/20 0.37
LRRK2 Q5S007 1/20 0.37
G6PD P11413 1/20 0.36
CYP3A4 P08684 7/20 0.35
CYP3A5 P20815 3/20 0.35
BRAF P15056 1/20 0.35
CDC7 O00311 1/20 0.35
DBF4 Q9UBU7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10696476 0.78 BRD4 (0.47) BRD4ALDH1A1PDPK1LMNACYP3A4
SCHEMBL10695889 0.75 CDK2 (0.48) BRD4ALDH1A1PDPK1LMNA
SCHEMBL10695854 0.74 CDK2 (0.49) BRD4ALDH1A1PDPK1LMNACYP3A4
SCHEMBL10697819 0.74 BRAF (0.41) BRD4ALDH1A1PDPK1LMNAG6PD
SCHEMBL3974202 0.74 ALDH1A1 (0.46) BRD4ALDH1A1PDPK1PI4KAPI4K2B
SCHEMBL5417230 0.70 NOS2 (0.39)
SCHEMBL7108989 0.69 PI4KA (0.50) BRD4ALDH1A1PDPK1PI4KAPI4K2B
SCHEMBL2493987 0.69 BRD4 (0.51) BRD4ALDH1A1PDPK1PI4KAPI4K2B
SCHEMBL323982 0.69 ALDH1A1 (0.52) BRD4ALDH1A1PDPK1PI4KAPI4K2B
SCHEMBL22830483 0.69 ALDH1A1 (0.46) BRD4ALDH1A1PDPK1PI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
WO-2003040103-A1 β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) BRISTOL-MYERS SQUIBB COMPANY (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 BRD4 2240/4885ALDH1A1 839/4885PDPK1 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.